Drug Database
Back to search

Poland· PL-100386232

Xeljanz

A tofacitinib product containing tofacitinibum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 2 of our 19 countries.

ATC L04AA29

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedXeljanzATCL04AA29REGISTER NO.PL-100386232PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tofacitinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tofacitinib is registered in 2 of 19 countries.

Countries holding a registration under ATC L04AA29 (tofacitinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 1 of them publish a price we can compare per daily dose
Search tofacitinib products by name

Tofacitinib · ATC L04AA29

2 / 19 countries

  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Tofacitinibum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
L04AA29
ATC class
Tofacitinib
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05907636977100
  • gtin
    05907636977117
  • gtin
    05907636977124

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

512 interactions on record for tofacitinib.

Graded by severity as the source publishes them — 333 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tofacitinib against other medicinesHow interaction checks work

Tofacitinib · interactions on record

512 records

  • 333 severe
  • 171 moderate
  • 8 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tofacitinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tofacitinib products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Tofacitinib Devatis, Tofacitinib Stada
  • Bulgaria · Tофацитиниб Devatis
  • Denmark · Tofacitinib Accord, Tofacitinib Newbury
  • Spain · Tofacitinib Stada
  • Finland · Tofacitinib Devatis, Tofacitinib Stada
  • France · Tofacitinib Stada
  • United Kingdom (Northern Ireland) · Tofacitinib Amarox, Tofacitinib Brown & Burk Uk
  • Croatia · Tofacitinib Accord, Tofacitinib Stada
  • Iceland · Xeljanz
  • Liechtenstein · Xeljanz
  • Malta · Tofacitinib Stada
  • Netherlands · Tofacitinib Devatis, Tofacitinib Stada
  • Norway · Tofacitinib Accord, Tofacitinib Devatis
  • Portugal · Tofacitinib Bluepharma
  • Sweden · Tofacitinib Devatis, Tofacitinib Newbury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/be09a786-683e-4860-bdd9-5cdd6174a1f2
GET /v1/drugs/be09a786-683e-4860-bdd9-5cdd6174a1f2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "05907636977100 ¦ Rpz ¦ EU/1/17/1178/003 ¦ 121538\n56 tabl.\n05907636977117 ¦ Rpz ¦ EU/1/17/2278/001 ¦ 121539\n60 tabl.\n05907636977124 ¦ Rpz ¦ EU/1/17/1178/002 ¦ 121540\n180 tabl.\nRpz ¦ EU/1/17/1178/004 ¦ 125457\n182 tabl.\nRpz ¦ EU/1/17/1178/014 ¦ 130033\n112 tabl.",
  "substance": "Tofacitinibi citras 5 mg",
  "common_name": "Tofacitinibum",
  "pl_product_id": "100386232",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about tofacitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console